SCHEMBL20416865

SCHEMBL20416865

CC#Cc1cc(-c2cccc(C#N)c2)nc(N)n1

nearest known ligand 0.55

Predicted protein targets (top 10)

geneUniProtsupporting neighboursconfidence
XDH P47989 1/20 0.50
ADORA2A P29274 6/20 0.49
ADORA1 P30542 3/20 0.49
CTSS P25774 1/20 0.46
CTSK P43235 1/20 0.46
HRH4 Q9H3N8 1/20 0.44
IDO1 P14902 1/20 0.43
KDM1A O60341 1/20 0.41
CLK4 Q9HAZ1 1/20 0.41
ATR Q13535 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31108332 0.84 XDH (0.45) XDHADORA2AADORA1CTSSCTSK
SCHEMBL20416555 0.83 XDH (0.52) XDHADORA2AADORA1CTSSCTSK
SCHEMBL30401905 0.83 XDH (0.52) XDHADORA2AADORA1CTSSCTSK
SCHEMBL20436452 0.83 ADORA2A (0.49) XDHADORA2AADORA1CTSSCTSK
SCHEMBL1357565 0.80 XDH (0.55) XDHADORA2AADORA1CTSSCTSK
SCHEMBL2881992 0.77 HSP90AA1 (0.61) XDHADORA2AADORA1CTSSCTSK
SCHEMBL29672835 0.77 HSP90AA1 (0.61) XDHADORA2AADORA1CTSSCTSK
SCHEMBL15757631 0.77 XDH (0.51) XDHADORA2AADORA1CTSSCTSK
SCHEMBL6023995 0.77 XDH (0.51) XDHADORA2AADORA1CTSSCTSK
SCHEMBL6023897 0.75 XDH (0.49) XDHADORA2AADORA1CTSSCTSK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4310082-A2 AZOLOPYRIMIDINE FOR THE TREATMENT OF CANCER-RELATED DISORDERS Arcus Biosciences, Inc. (US) 2024-01-24 EP disclosed
EP-3570844-B1 AZOLOPYRIMIDINE FOR THE TREATMENT OF CANCER-RELATED DISORDERS ARCUS BIOSCIENCES INC (US) 2023-09-06 EP disclosed
US-20220144808-A1 AZOLOPYRIMIDINE FOR THE TREATMENT OF CANCER-RELATED DISORDERS ARCUS BIOSCIENCES, INC. 2022-05-12 US disclosed
US-11072597-B2 Azolopyrimidine for the treatment of cancer-related disorders ARCUS BIOSCIENCES, INC. 2021-07-27 US disclosed
US-20210101880-A1 AZOLOPYRIMIDINE FOR THE TREATMENT OF CANCER-RELATED DISORDERS ARCUS BIOSCIENCES, INC. 2021-04-08 US disclosed
US-20180215730-A1 AZOLOPYRIMIDINE FOR THE TREATMENT OF CANCER-RELATED DISORDERS ARCUS BIOSCIENCES, INC. 2018-08-02 US disclosed
US-20180215730-A1 AZOLOPYRIMIDINE FOR THE TREATMENT OF CANCER-RELATED DISORDERS ARCUS BIOSCIENCES, INC. 2018-08-02 US disclosed
WO-2018136700-A1 AZOLOPYRIMIDINE FOR THE TREATMENT OF CANCER-RELATED DISORDERS ARCUS BIOSCIENCES, INC. (US) 2018-07-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220144808-A1 AZOLOPYRIMIDINE FOR THE TREATMENT OF CANCER-RELATED DISORDERS ADORA2A, ADORA2B, ADORA1 XDH 412/4885ADORA2A 1/4885ADORA1 3/4885
US-11072597-B2 Azolopyrimidine for the treatment of cancer-related disorders ADORA2A, ADORA2B, ADORA1 XDH 412/4885ADORA2A 1/4885ADORA1 3/4885
US-20180215730-A1 AZOLOPYRIMIDINE FOR THE TREATMENT OF CANCER-RELATED DISORDERS ADORA2A, ADORA2B, ADORA1 XDH 412/4885ADORA2A 1/4885ADORA1 3/4885
US-20210101880-A1 AZOLOPYRIMIDINE FOR THE TREATMENT OF CANCER-RELATED DISORDERS ADORA2A, ADORA2B, ADORA1 XDH 412/4885ADORA2A 1/4885ADORA1 3/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.